LymphedemaV1, PubMed, Curation, bibRecord, 000217

Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More.

Identifieur interne : 000217 ( PubMed/Curation ); précédent : 000216; suivant : 000218

Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More.

Auteurs : Mario M. Leitao [Danemark]

Source :

Current obstetrics and gynecology reports [ 2161-3303 ] ; 2016.

RBID : pubmed:28484664

Abstract

The role and extent of lymphadenectomy for endometrial carcinoma has been debated for over 30 years. Many clinicians argue that there is therapeutic value for lymphadenectomy in patients deemed to be "at risk", a designation not universally defined, despite the lack of randomized data supporting this argument. However, lymphadenectomy is associated with morbidity, including lower extremity lymphedema. Sentinel lymph node (SLN) mapping is emerging as a viable alternative to comprehensive lymphadenectomy in the surgical staging of patients with endometrial cancer.

DOI: 10.1007/s13669-016-0178-7
PubMed: 28484664

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000217

Links to Exploration step

pubmed:28484664

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More.</title>
<author><name sortKey="Leitao, Mario M" sort="Leitao, Mario M" uniqKey="Leitao M" first="Mario M" last="Leitao">Mario M. Leitao</name>
<affiliation wicri:level="1"><nlm:affiliation>Attending Surgeon, Member, Division of Gynecology, Professor, Weill Cornell Medical College, Director, Gynecologic Oncology Fellowship Program, Director, Minimal Access and Robotic Surgery (MARS) Program, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065,.</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Attending Surgeon, Member, Division of Gynecology, Professor, Weill Cornell Medical College, Director, Gynecologic Oncology Fellowship Program, Director, Minimal Access and Robotic Surgery (MARS) Program, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:28484664</idno>
<idno type="pmid">28484664</idno>
<idno type="doi">10.1007/s13669-016-0178-7</idno>
<idno type="wicri:Area/PubMed/Corpus">000217</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000217</idno>
<idno type="wicri:Area/PubMed/Curation">000217</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000217</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More.</title>
<author><name sortKey="Leitao, Mario M" sort="Leitao, Mario M" uniqKey="Leitao M" first="Mario M" last="Leitao">Mario M. Leitao</name>
<affiliation wicri:level="1"><nlm:affiliation>Attending Surgeon, Member, Division of Gynecology, Professor, Weill Cornell Medical College, Director, Gynecologic Oncology Fellowship Program, Director, Minimal Access and Robotic Surgery (MARS) Program, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065,.</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Attending Surgeon, Member, Division of Gynecology, Professor, Weill Cornell Medical College, Director, Gynecologic Oncology Fellowship Program, Director, Minimal Access and Robotic Surgery (MARS) Program, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Current obstetrics and gynecology reports</title>
<idno type="ISSN">2161-3303</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The role and extent of lymphadenectomy for endometrial carcinoma has been debated for over 30 years. Many clinicians argue that there is therapeutic value for lymphadenectomy in patients deemed to be "at risk", a designation not universally defined, despite the lack of randomized data supporting this argument. However, lymphadenectomy is associated with morbidity, including lower extremity lymphedema. Sentinel lymph node (SLN) mapping is emerging as a viable alternative to comprehensive lymphadenectomy in the surgical staging of patients with endometrial cancer.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28484664</PMID>
<DateCreated><Year>2017</Year>
<Month>05</Month>
<Day>09</Day>
</DateCreated>
<DateRevised><Year>2017</Year>
<Month>08</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2161-3303</ISSN>
<JournalIssue CitedMedium="Print"><Volume>5</Volume>
<Issue>4</Issue>
<PubDate><Year>2016</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Current obstetrics and gynecology reports</Title>
<ISOAbbreviation>Curr Obstet Gynecol Rep</ISOAbbreviation>
</Journal>
<ArticleTitle>Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More.</ArticleTitle>
<Pagination><MedlinePgn>279-285</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s13669-016-0178-7</ELocationID>
<Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">The role and extent of lymphadenectomy for endometrial carcinoma has been debated for over 30 years. Many clinicians argue that there is therapeutic value for lymphadenectomy in patients deemed to be "at risk", a designation not universally defined, despite the lack of randomized data supporting this argument. However, lymphadenectomy is associated with morbidity, including lower extremity lymphedema. Sentinel lymph node (SLN) mapping is emerging as a viable alternative to comprehensive lymphadenectomy in the surgical staging of patients with endometrial cancer.</AbstractText>
<AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Nodal disease status is an important prognostic and predictive factor. Surgical staging with lymphadenectomy remains an important part of the treatment of patients with newly diagnosed endometrial carcinoma despite the dispute regarding its therapeutic value. Many clinicians have argued for abandoning lymphadenectomy altogether; however, this too is not ideal, as it may lead to under-treatment due to inadequate staging or over-treatment with toxic therapies.</AbstractText>
<AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">SLN mapping has emerged as a viable compromise between a comprehensive lymphadenectomy and no lymph node sampling in the surgical staging of these patients, and may lead to reduced morbidity risks. In this review, we present the currently available data in this area of research, as well as our experience with SLN mapping.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leitao</LastName>
<ForeName>Mario M</ForeName>
<Initials>MM</Initials>
<Suffix>Jr</Suffix>
<AffiliationInfo><Affiliation>Attending Surgeon, Member, Division of Gynecology, Professor, Weill Cornell Medical College, Director, Gynecologic Oncology Fellowship Program, Director, Minimal Access and Robotic Surgery (MARS) Program, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065,.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>10</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Curr Obstet Gynecol Rep</MedlineTA>
<NlmUniqueID>101579335</NlmUniqueID>
<ISSNLinking>2161-3303</ISSNLinking>
</MedlineJournalInfo>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2009 Jan 10;373(9658):125-36</RefSource>
<PMID Version="1">19070889</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16</RefSource>
<PMID Version="1">19033573</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 1998 Aug;70(2):163-4</RefSource>
<PMID Version="1">9740683</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2016 Mar;140(3):394-9</RefSource>
<PMID Version="1">26747778</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Gynecol Cancer. 2013 Jun;23(5):964-70</RefSource>
<PMID Version="1">23694985</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 1991 Jan;40(1):55-65</RefSource>
<PMID Version="1">1989916</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2009 Aug 13;361(7):653-63</RefSource>
<PMID Version="1">19675329</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2016 Aug;23(8):2522-8</RefSource>
<PMID Version="1">26905542</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2014 Aug;134(2):385-92</RefSource>
<PMID Version="1">24905773</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Gynecol Oncol. 2016 Jan;27(1):e1</RefSource>
<PMID Version="1">25925293</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Apr 10;26(11):1803-9</RefSource>
<PMID Version="1">18332473</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Mar 6;375(9717):816-23</RefSource>
<PMID Version="1">20206777</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2016 May;23 (5):1653-9</RefSource>
<PMID Version="1">26714954</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2014 Jan;132(1):38-43</RefSource>
<PMID Version="1">24120926</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 1987 Oct 15;60(8 Suppl):2035-41</RefSource>
<PMID Version="1">3652025</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2012 Jun;125(3):531-5</RefSource>
<PMID Version="1">22366409</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2014 Aug;134(2):393-402</RefSource>
<PMID Version="1">24929052</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2012 Apr;125(1):87-93</RefSource>
<PMID Version="1">22155678</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2013 Apr;129(1):38-41</RefSource>
<PMID Version="1">23321065</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Obstet Gynecol. 2014 Aug;124(2 Pt 1):307-15</RefSource>
<PMID Version="1">25004343</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2006 Jan 1;24(1):36-44</RefSource>
<PMID Version="1">16330675</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2013 Dec;131(3):714-9</RefSource>
<PMID Version="1">24099838</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Apr 3;375(9721):1165-72</RefSource>
<PMID Version="1">20188410</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2011 May;12 (5):469-76</RefSource>
<PMID Version="1">21489874</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 1995 Jan;56(1):29-33</RefSource>
<PMID Version="1">7821843</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2012 Nov;127(2):332-7</RefSource>
<PMID Version="1">22910695</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2000 Apr 22;355(9213):1404-11</RefSource>
<PMID Version="1">10791524</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30</RefSource>
<PMID Version="1">26742998</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2011 Dec;123(3):522-7</RefSource>
<PMID Version="1">21945553</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2006 Oct 15;107(8):1823-30</RefSource>
<PMID Version="1">16977653</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2015 Jul;138(1):41-5</RefSource>
<PMID Version="1">25891803</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">endometrial cancer</Keyword>
<Keyword MajorTopicYN="N">lymphadenectomy</Keyword>
<Keyword MajorTopicYN="N">sentinel lymph node</Keyword>
<Keyword MajorTopicYN="N">sentinel lymph node mapping</Keyword>
</KeywordList>
<CoiStatement>Conflict of Interest: Mario M. Leitao, Jr. declares no conflict of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year>
<Month>12</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>5</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>5</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>5</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28484664</ArticleId>
<ArticleId IdType="doi">10.1007/s13669-016-0178-7</ArticleId>
<ArticleId IdType="pmc">PMC5419688</ArticleId>
<ArticleId IdType="mid">NIHMS820748</ArticleId>
</ArticleIdList>
<pmc-dir>nihms</pmc-dir>
    </PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000217 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000217 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:28484664
   |texte=   Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:28484664" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More.

Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki